Study Summary
This trial will assess if a drug, VTX958, is safe & effective in adults with Psoriatic Arthritis. 195 people will take VTX958 or placebo for 16 weeks. Follow up 30 days later.
- Psoriatic Arthritis
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 5 Secondary · Reporting Duration: Week 16
Trial Safety
Phase-Based Safety
Trial Design
3 Treatment Groups
VTX958 Dose A
1 of 3
VTX958 Dose B
1 of 3
Placebo
1 of 3
Experimental Treatment
Non-Treatment Group
195 Total Participants · 3 Treatment Groups
Primary Treatment: VTX958 Dose A · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 75 · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is the target demographic for this research confined to individuals aged 25 and above?
"This medical trial is available to individuals aged 18 and up, but not exceeding 75 years." - Anonymous Online Contributor
What measures have been taken to mitigate the risks of VTX958 Dose A?
"Based on the available evidence, VTX-958 Dose A was concluded to have an estimated safety rating of 2. This is due to this being a Phase 2 trial and thus lack of proof for efficacy but some data indicating its relative safety." - Anonymous Online Contributor
Is the research team currently accepting participants for this investigation?
"Yes, the information hosted on clinicaltrials.gov suggests that this experiment is currently looking for participants to enroll. It was initially posted in January 31st 2023 and updated most recently on February 4th of the same year. The trial requires 195 patients between two sites to be enrolled." - Anonymous Online Contributor
How many people are participating in this clinical experiment?
"Affirmative. Clinicaltrials.gov shows us that this medical trial was posted on January 31st 2023 and has been updated recently on February 4th 2023, thus actively recruiting patients for enrollment at two separate sites with a total requirement of 195 participants." - Anonymous Online Contributor
What is the primary intent of this medical experiment?
"This clinical trial, monitored over 16 weeks, aims to gauge the frequency of Treatment Emergent Adverse Events (TEAEs) from Week 0 until Week 16. Auxiliary objectives include: establishing the proportion of patients achieving 75% reduction in their Psoriasis Area and Severity Index (PASI75), measuring changes in Short Form Health Survey - 36 items' (SF-36's) physical component score (PCS) at Week 16, and assessing the number of participants reaching American College of Rheumatology criteria ACR50 by week sixteen." - Anonymous Online Contributor
What criteria must potential participants meet to be eligible for this research initiative?
"This clinical trial is accepting 195 participants who are between 18 and 75 years old, diagnosed with psoriatic arthritis for at least 6 months, present active signs of [plaque psoriasis](https://www.withpower.com/clinical-trials/plaque-psoriasis) or nail changes related to psoriasis, have 3 swollen joints and 3 tender joints upon screening as well as day one. Women must not be able to conceive or use highly effective contraception during the study and 30 days after the last dose while men in relationships with women capable of becoming pregnant must wear condoms throughout the duration of the experiment plus an additional 90 days following their final dose." - Anonymous Online Contributor